Akums Drugs & Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • CDMO: 80.1% • Branded & Generic Formulations: 12.7% • API: 5.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Latest quarter profit grew 56.1% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.57x)
- Company generates healthy free cash flow
- Institutional investors have been accumulating - FII+DII up 2.3pp
CONS
- Recent results are weak - TTM profit is down 31.7% versus prior year
- A large part of profit comes from other income (33.7% of PBT)
- Promoter holding has decreased over last 2 years: -9.6pp
- Company has a low return on equity of 8.8% over last 3 years
- Company has a low return on capital employed of 11.0%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1864.00 | 36.98 | 447236.04 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9405.00 | 85.36 | 249673.20 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4928.40 | 85.95 | 187460.49 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1118.00 | 24.71 | 111520.93 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1380.00 | 33.08 | 111484.47 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1936.00 | 95.67 | 104604.45 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1669.00 | 25.87 | 96030.57 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| DRREDDY | 1140.80 | 29.55 | 95220.28 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| LUPIN | 2075.00 | 17.16 | 94882.67 | 0.87 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2246.00 | 45.42 | 92769.93 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2417.00 | 37.94 | 68213.70 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| AKUMS | 750.10 | 40.47 | 11806.12 | 0.40 | 100.98 | 56.11 | 1166.63 | 13.93 | 14.77 | 14.97 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | |
| 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 1,058 | |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 109 |
| OPM % | -12.92% | 12.85% | 8.63% | 0.32% | 12.56% | 11.73% | 12.01% | 8.90% | 12.59% | 9.29% | 12.66% | 13.10% | 9.33% |
| 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 | |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before Tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | -18.03% | 62.48% | -228.95% | -20.04% | 30.03% | 27.23% | 27.17% | -99.11% | 32.37% | 34.99% | 32.03% | 32.89% | 27.48% |
| Net Profit | 0 | 0 | 0 | 0 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| -13.16 | 2.22 | 13.21 | -2.89 | 4.21 | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,857 | 1,552 | 2,008 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 | |
| 1,663 | 1,353 | 1,826 | 2,240 | 2,431 | 3,764 | 3,361 | 4,055 | 3,658 | 3,837 | 4,000 | |
| Operating Profit | 195 | 199 | 182 | 174 | 291 | -92 | 294 | 123 | 461 | 522 | 502 |
| OPM % | 10.48% | 12.85% | 9.08% | 7.21% | 10.69% | -2.50% | 8.04% | 2.94% | 11.18% | 11.98% | 11.15% |
| 9 | 15 | 22 | 26 | -43 | 10 | 16 | 8 | 73 | 109 | 112 | |
| Interest | 16 | 13 | 23 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 46 | 52 | 56 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before Tax | 143 | 150 | 126 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 32.99% | 39.54% | 45.99% | 61.65% | 28.34% | -29.85% | 34.92% | 101.74% | 0.43% | 32.90% | 31.24% |
| Net Profit | 96 | 90 | 68 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS | 813.00 | 777.00 | 579.00 | 357.03 | 17.26 | -17.65 | 6.63 | -0.28 | 22.09 | 16.67 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 10%
- 5 Years:
- 10%
- 3 Years:
- 6%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 15%
- 5 Years:
- 16%
- 3 Years:
- 39%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 69%
RETURN ON EQUITY
- 10 Years:
- 6%
- 5 Years:
- 2%
- 3 Years:
- 9%
- Last Year:
- 8%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Minority Interest | 21 | 29 | 35 | -2 | 2 | 3 | 6 | 11 | 17 | 18 |
| 710 | 794 | 855 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 | |
| 189 | 170 | 238 | 699 | 736 | 1,458 | 1,651 | 1,910 | 115 | 1,028 | |
| Trade Payables | 147 | 244 | 210 | 423 | 341 | 590 | 567 | 532 | 643 | 602 |
| 132 | 152 | 195 | 194 | 188 | 378 | 293 | 231 | 84 | 315 | |
| Total Liabilities | 1,200 | 1,389 | 1,535 | 2,037 | 2,152 | 3,050 | 3,235 | 3,393 | 3,905 | 5,276 |
| 603 | 649 | 652 | 644 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 | |
| Capital Work in Progress | 0 | 0 | 0 | 57 | 17 | 31 | 103 | 195 | 160 | 177 |
| 0 | 12 | 9 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | |
| 244 | 295 | 268 | 398 | 430 | 722 | 730 | 630 | 681 | 756 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 834 | 770 | 797 | |
| Cash & Bank | 7 | 18 | 21 | 147 | 68 | 103 | 150 | 277 | 576 | 1,681 |
| 346 | 415 | 585 | 784 | 714 | 1,173 | 1,155 | 266 | 321 | 411 | |
| Total Assets | 1,200 | 1,389 | 1,535 | 2,037 | 2,152 | 3,050 | 3,235 | 3,393 | 3,905 | 5,276 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 194 | 204 | 28 | 77 | 179 | 87 | 274 | 498 | 465 | 1,181 | |
| Cash from Investing | -128 | -111 | -49 | -190 | -109 | -235 | -305 | -330 | -548 | -930 |
| Cash from Financing | -34 | -35 | 75 | 233 | -95 | 236 | 125 | -108 | 73 | 34 |
| -7 | 11 | 3 | 71 | -70 | 33 | -4 | 60 | -10 | 285 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Intimation of ESG Rating
2026-08-25 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-24 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026
2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript
2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of Recording
2026-08-10 - Copy of Newspaper Publication
2026-08-10 - Monitoring Agency Report for the quarter ended June 30, 2026
News
Recent coverage and analyst commentary for AKUMS
Loading news…
AI Stock Analyst
Akums Drugs & Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account